APP下载

益气解毒调和肝脾法治疗恶性血液病伴抑郁状态的临床研究

2018-09-10郎立新王晓波杨淑莲周振环汤久慧杨博孙长勇李欲来

世界中医药 2018年7期

郎立新 王晓波 杨淑莲 周振环 汤久 慧杨博 孙长勇 李欲来

摘要目的:觀察益气解毒调和肝脾法治疗恶性血液病伴抑郁状态疗效及对T淋巴细胞亚群水平的影响。方法:采用随机数字表法,将60例门诊及住院辨证为正气虚弱、邪毒内蕴、肝郁脾虚型的恶性血液病伴抑郁状态患者随机分为2组。对照组30例口服帕罗西汀20 mg/d,1次/d,早餐时顿服,药片完整吞服。观察组30例在此治疗基础上给予参芪杀白汤合四逆散加减,水煎400 mL,早晚饭后口服。连续治疗6周。于治疗前及治疗2周、4周和6周后观察临床症状及HAMD评分,以及于治疗前后检测外周血T淋巴细胞亚群的水平。结果:治疗6周后,观察组有效8例,显效13例,痊愈6例,无效3例,总有效率90%;对照组有效10例,显效9例,痊愈2例,无效9例,总有效率70%。观察组临床疗效明显优于对照组(P<005)。与治疗前比较,治疗2周、4周和6周后,2组HAMD评分均较治疗前低,差异有统计学意义(P均<005)。而且从治疗2周后,观察组的HAMD评分改善程度优于对照组,差异有统计学意义(P均<005)。治疗前2组CD3+、CD4+、CD4+/CD8+均显著降低,CD8+显著升高,2组之间的差异均无统计学意义(P均>005);治疗6周后,2组CD3+、CD4+、CD4+/CD8+均显著升高(P均<005),CD8+均显著降低(P均<005),而且观察组改善程度显著优于对照组(P均<005)。结论:益气解毒调和肝脾法治疗恶性血液病伴抑郁状态疗效显著,不良反应小,安全性高,并且可以显著提高本病患者的免疫功能,值得推广。

关键词参芪杀白汤;四逆散;帕罗西汀;恶性血液病;抑郁症;T淋巴细胞亚群;益气解毒;和肝脾

Clinical Study on the Treatment of Hematologic Malignancies with Depression by Replenishing Qi and Removing Toxicity and Harmonizing the LiverSpleen Method

Lang Lixin, Wang Xiaobo, Yang Shulian, Zhou Zhenhuan, Tang Jiuhui, Yang Bo, Sun Changyong, Li Yulai

(Langfang Traditional Chinese Medicine Hospital, Langfang 065000, China)

AbstractObjective:To observe antidepressant effect and changing levels of T lymphocyte subsets in patients suffered from hematologic malignancies and depression by replenishing qi and removing toxicity and harmonizing the liverspleen method. Methods:A total of 60 cases from outpatients and hospitalized patients suffered from hematologic malignancies with depression and belong to syndrome of vital qi deficiency, internal accumulation of pathogenic factors and liver stagnation and spleen deficiency were randomly divided into two groups with a method of random number table. The control group (n=30) took paroxetine 20 mg/d once per day orally and swallowed pills completely at breakfast. The treatment group based on what the control group do (n=30) was given additional 400 mL modified Shenqi Shabai Decoction and Sini Powder, l after the breakfast and the dinner. One course lasted for 6 weeks. Before treatment and 2 weeks, 4 weeks and 6 weeks after treatment, HAMD scores and clinical symptoms were recorded as well as levels of peripheral blood T lymphocyte subsets. Results:After 6 weeks treatment, there were 8 effective cases, 13 markedly effective cases and 6 cases being cured and no effect in 3 cases in the treatment group and the total effective rate was 90%; while in the control group, there were 10 effective cases, 9 markedly effective cases and 2 cases being cured and no effect in 9 cases, and the total effective rate was 70%. Clinical efficacy of treatment group was obviously better than that of the control group (P<005). HAMD scores of the two groups lowered after 2 weeks, 4 weeks and 6 weeks of treatment than before the treatment, and there were statistically significant differences (all P<005). Since 2 weeks after treatment, improvement of HAMD scores in the treatment group was higher than that of the control group, and there were significant differences (all P<005). Levels of CD3+, CD4+ and ratio of CD4+/CD8+ were significantly reduced in the two groups before the treatment, but level of CD8+ increased significantly. There was no significant difference between the two groups (all P>005). But after 6 weeks, levels of CD3+, CD4+ and ratio of CD4+/CD8+ were significantly increased in the two groups (all P<005), and level of CD8+ was significantly descended (all P<005). The improvement degree of the treatment group was significantly higher than that of the control group (all P<005). Conclusion:Therapy of Shenqi Shabai Decoction and Sini Powder combined with paroxetine for patients suffered from hematologic malignancies with depression has a distinct curative effect with fewer side effects and high safety, which can significantly improve patient′s immune function and is worth to promote.

Key WordsShenqi Shabai Decoction; Sini Powder; Paroxetine; Hematologic Malignancies; Depression; T subgroup; Replenishing qi and removing toxicity and harmonizing the liverspleen

中图分类号:R273文献标识码:Adoi:10.3969/j.issn.1673-7202.2018.07.031

恶性血液病(包括急慢性白血病、淋巴瘤、多发性骨髓瘤等恶性克隆性疾病)伴抑郁状态严重影响患者生命质量的身心疾病。研究显示,2013我国恶性血液病患者抑郁发生率为349%,并呈逐年上升的趋势[1]。目前尚无法满意控制这些患者的抑郁状态。新一类抗抑郁药——选择性5羟色胺抑制剂(SSRI)的应用,使抑郁症的药物治疗取得重大进展,帕罗西汀(Paroxetine)是一种高效安全的SSRI[2]。研究证实,抑郁症患者存在不同程度T淋巴细胞亚群数目变化,推测T淋巴细胞亚群比例失衡与抑郁症严重程度存在一定相关性[3]。……

登录APP查看全文